Klotho Neurosciences Surges to 59th in Daily Rankings with 11.63 Billion Turnover

On June 9, 2025, Klotho Neurosciences (KLTO) experienced a significant surge in trading volume, with a turnover of 11.63 billion, marking a 15824.1% increase from the previous day. This substantial rise placed KLTO at the 59th position in the daily stock market rankings. The stock has been on a remarkable upward trajectory, rising by 787.80% over the past four days, with a cumulative increase of 944.18% during this period.

Klotho Neurosciences has made significant strides in longevity research, focusing on the Klotho gene. The company has secured exclusive worldwide licenses for s-KL protein technology, which has shown promising results in extending lifespan and improving healthspan. Recent studies published in Molecular Therapy demonstrated that genetic overexpression of Klotho increased mouse lifespan by 30-40%, while the secreted form (s-KL) showed a 20% lifespan increase. The research revealed s-KL's potential in addressing age-related conditions including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis.

Klotho Neurosciences is strategically targeting neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, which represent massive market opportunities with significant unmet needs. The company's lead drug candidate, KLTO-101, has received FDA clearance to conduct a Phase Ib/IIa clinical trial in patients with early-stage Alzheimer's. This mechanistic approach, targeting fundamental aging processes rather than just symptoms, showcases the company's scientific sophistication and potential for broader anti-aging therapeutics.